argyrotsipi/train-dataset huggingface dataset:
Brexit Readiness: Operation Yellowhammer — House of Commons, 2019-09-25
Topic: Health
Janet Jessica Daby (Labour, Centre-left): Like the right hon. Member for Basingstoke (Mrs Miller) and my hon. Friend the Member for Washington and Sunderland West (Mrs Hodgson), I am concerned about the supply of medicines in the event of a no-deal Brexit, especially when a constituent of mine, Des, tells me that his local pharmacy is not receiving certain prescriptions because the suppliers say they are not sure what will happen after 31 October. What would the right hon. Gentleman say to my constituent, and what steps is he taking to ensure the supply of medicines for hospitals and independent pharmacies in the event of a no-deal Brexit?
Brexit Readiness: Operation Yellowhammer — House of Commons, 2019-09-25
Topic: Health
Tracy Lynn Brabin (Labour, Centre-left): Picking up on the questions from my hon. Friend the Member for Lewisham East (Janet Daby) and the right hon. Member for Basingstoke (Mrs Miller), Primary Care Network Leeds has told me that shortages are already being caused by the stockpiling of HRT and Naproxen, a painkiller, and the health unions say that no deal could devastate the NHS and cause fatal shortages of medicines. Can the Minister tell us now that no one in this country will suffer in their health because of a no-deal Brexit?
Brexit Readiness: Operation Yellowhammer — House of Commons, 2019-09-25
Topic: Health
Catherine Jane Smith (Labour, Centre-left): My constituent Jenny is currently undergoing treatment for cancer and has been seeking reassurances from local health trusts about the continuation of cancer treatment in the event of a no-deal exit from the European Union. As her constituency MP, I have also submitted freedom of information requests, including to Blackpool Teaching Hospitals NHS Foundation Trust, seeking the risk assessments in the event of a no-deal exit, but it has not shared that information with me. My constituent Jenny is also concerned about the capacity of UK ports to bring in nuclear medicines in the event of a no-deal exit. What assessment has the Minister made of the capacity of UK ports to bring in important medicines, including for cancer treatment, insulin for diabetics and formula milk for formula-fed babies?
Brexit Readiness: Operation Yellowhammer — House of Commons, 2019-09-25
Topic: Health
Christopher Shaun Ruane (Labour, Centre-left): The Yellowhammer report warns of shortages of key drugs and medicines. Can the Minister supply the House with a list of those medicines that are likely to be in short supply? If there is scarcity, what measures are in place to ensure fair and equitable distribution of those scarce medicines across the nations and regions of the United Kingdom?
Brexit Readiness: Operation Yellowhammer — House of Commons, 2019-09-25
Topic: Defense
Justin Piers Richard Madders (Labour, Centre-left): Does the Secretary of State envisage using powers available to him under the Civil Contingencies Act 2004, and if so, what might he use them for? In those circumstances, can he guarantee that Parliament will remain open to ensure that there is scrutiny of those powers?
Spending Round 2019 — House of Commons, 2019-09-04
Topic: Health
Seema Malhotra-Saluja (Labour, Centre-left): I look forward to sharing plans for the Southern Rail access to Heathrow, which I hope will form an important part of the Chancellor’s new infrastructure strategy This month, Hounslow clinical commissioning group was due to present the full business case for the planned and urgently needed Heston health centre redevelopment to its governing body. However, the project is on hold after questions about whether the local improvement finance trust scheme, which was originally advised by the Department of Health and Social Care as the best-value funding option, could still go ahead following confusion around the Treasury’s policy on LIFT schemes last year. Will the Chancellor meet me to review the situation, so that we can see whether the existing plans can be approved or whether any of the alternative capital funding he has announced will be available to enable this important and urgent development to go ahead?
Batten Disease — House of Commons, 2019-07-22
Topic: Health
Sharon Hodgson (Labour, Centre-left): Thank you, Mr Speaker, for granting this urgent question. I thank and congratulate the hon. Member for North East Somerset (Mr Rees-Mogg) for securing it following his Adjournment debate last week. I do not doubt that he would have preferred the Minister to have come before the House voluntarily, rather than being forced to come here today for his urgent question. Time and again, we come to this place to talk about a drug and its benefits to patients, only to be told that no matter how good it is, people cannot access it on the NHS. Among all the politics, there are people, including children like Max, who are suffering. No parent wants to hear a critical diagnosis for their child who has not yet really experienced childhood, let alone reached adulthood As we have heard, Brineura, a drug made available by BioMarin, could stop the progression of Batten disease. An assessment by NICE has found that Brineura could provide 30 extra years of good-quality life to patients. But, as has become expected when we discuss drugs for rare diseases in this place, Brineura is not available for patients on the NHS. NICE confirmed earlier this year that it was unable to recommend the use of Brineura on the NHS because of cost-effectiveness. The drug costs over £500,000 per person for each year’s treatment. BioMarin has another drug for rare diseases—Kuvan, for patients with phenylketonuria, or PKU. PKU patients do not have access to Kuvan, because it is also deemed not to be cost-effective. Does the Minister agree that the NICE appraisal process is just not fit for purpose when it comes to assessing the suitability of drugs and treatments for rare diseases Access to Brineura would help to give patients and families their child back, and it would allow them to enjoy time with their child and treasure special moments with them. As time ticks on without access to the drug, parents will witness their child’s condition deteriorate. No parent wants to see that, so we really need an appraisal process that captures rare diseases effectively Will the Minister step in and personally urge BioMarin, NHS England and NICE to meet and come to an agreement? Families do not just want warm words from the Minister; they want and need access to medicines now. I hope that this urgent question will result in real change in how we address rare diseases.
Batten Disease — House of Commons, 2019-07-22
Topic: Health
Catherine McKinnell (Labour, Centre-left): Thank you, Mr Speaker, for granting this urgent question. I thank the hon. Member for North East Somerset (Mr Rees-Mogg) for securing it. The families of children with Batten disease have been left dangling for far too long, and the delay in a positive decision being arrived at—for what is a really obvious use of NHS funding, if we were to ask any taxpayer out there —is just too painful for many of them to bear. The stress and anxiety they are being caused is completely unacceptable The Minister acknowledges that this is a dreadful disease, but it is a dreadful disease that has a treatment—a highly effective treatment. It does not just score 30 QALYs; it has been acknowledged that it scores way beyond that. NHS England is adhering to an arbitrary cap set by NICE. Will the Minister please confirm whether NHS England can use a budget exemption in these circumstances to deal with the very tiny number of children who are affected, and what will she do practically—and what has she done since last week—not just to urge but to get BioMarin round the table with NHS England and NICE to get a positive outcome for these families and these children?
Batten Disease — House of Commons, 2019-07-22
Topic: Health
Christopher John Bryant (Labour, Centre-left): There can be very few things as painful for a parent as knowing, once their child has been diagnosed, that there is potential treatment out there that may make a radical difference to their life, and it will feel as though some bureaucrats—whether or not they are medical bureaucrats—are saying no. These little things in my hand, which would not have been prescribed for me if I had gone to the doctor a year ago, now cost £7,000 a month to the NHS, and I am delighted that I am able to receive them. However, I do want to make sure we have a proper system to ensure, for the most rare conditions, that there really is a possibility of making things available There may only be three dozen cases in the UK at the moment, which means there are probably about 900 in Europe, and if we include the Commonwealth, probably several thousand more. Why do we not have Governments in the world sitting round the table together with people from the pharmaceutical companies, who are not the baddies in this—these are the people, I think including the hon. Member for North East Somerset (Mr Rees-Mogg), whose investment made these pills available for me, in part; investment in these pharmaceutical companies is a good thing—to make sure that more of these rare disease conditions can be treated?
Batten Disease — House of Commons, 2019-07-22
Topic: Health
Marie Elizabeth Rimmer (Labour, Centre-left): I thank the hon. Member for North East Somerset (Mr Rees-Mogg) for securing this urgent question Will the Minister, while working to secure the funding of the drug Brineura to help sufferers of Batten disease such as my young constituent Kaycee Bradshaw, look at how we can help to prevent companies such as BioMarin charging extortionate fees for life-changing drugs? Sadly, this company also charges beyond the NICE framework for Kuvan, a vital drug needed by my young constituent Liam, who suffers from PKU. BioMarin made a net-product revenue increase for 2018 of $31.3 million from Brineura and $26.1 million from Kuvan, and $1.5 billion from across its range of drugs. This, by my standards, is a clear example of playing profits with people’s lives. It hurts even more that it is children who are suffering. It is not on. It is time that Governments got together and took heed. We do not know what other countries are paying. It might be less than our £300,000 or it might not, but something must happen. Get together and put the pressure on, but please, please secure these drugs for our children.
Batten Disease — House of Commons, 2019-07-22
Topic: Health
Nicklaus Thomas-Symonds (Labour, Centre-left): Earlier in this Parliament, I supported a young constituent of mine in securing access to Brineura. Health is a devolved matter in Wales, but the NICE recommendations are still very important. The problem I have seen over the past four years, unfortunately, is that those guidelines do not work particularly well when a disease is extremely rare. Does the Minister plan to look again and review the guidelines, so that people are not penalised simply because the condition they have is rare?
Arms Export Licences (Saudi Arabia) — House of Commons, 2019-09-26
Topic: Defense
Ann Clwyd (Labour, Centre-left): Thank you, Mr Speaker Does the new Minister realise that it took almost a year, at the start of this Parliament, to set up the Committees on Arms Export Controls because the Government dragged their feet—and, I would say, dragged their feet deliberately? I am sick of hearing about "rigorous and robust"—this is neither rigorous nor robust. Representatives of the various parties in the Saudi-led coalition were recently at the arms fair. Can she give us an assurance that no new undertakings or contracts were agreed to service or export new goods to the countries involved in the coalition in Yemen?
Arms Export Licences (Saudi Arabia) — House of Commons, 2019-09-26
Topic: Defense
Eleanor Claire Reeves (Labour, Centre-left): Despite repeated assurances from the Government over the years that they had acted within the law concerning export licences for arms to Saudi Arabia, we found out last week that the Government had acted unlawfully and today that there might be further breaches. When will this Government recognise the plight facing the Yemeni people and immediately suspend all existing and future arms exports to Saudi Arabia?
Arms Export Licences (Saudi Arabia) — House of Commons, 2019-09-26
Topic: Defense
Stephen Twigg (Labour, Centre-left): The Court of Appeal identified a failure by the Government to meet their legal obligation to make a systematic assessment of past possible violations of international law. The Secretary of State today has acknowledged a failure to share information across Government. Surely these failures demonstrate that we no longer have a robust system of arms control in this country.
Arms Export Licences (Saudi Arabia) — House of Commons, 2019-09-26
Topic: Defense
Graham Peter Jones (Labour, Centre-left): May I make a declaration? I have just returned from a two-day visit to Abqaiq in Saudi Arabia, facilitated by the kingdom, and in the coming days I will include that in the Register of Members’ Financial Interests As Chair of the Committees on Arms Export Controls, I would like to thank the Secretary of State for writing to me immediately on this issue and making it very transparent what the problems were. The Kingdom of Saudi Arabia is fighting vile terrorists in Yemen who are using human shields. Does she agree that we are approaching the point where our current arms export regulations are not sufficient to deal with the issue of the rebels—the terrorists—using human shields and that the number of civilian casualties is a result of that?
Kashmir — House of Commons, 2019-09-03
Topic: Health
Hugh Lawrence Gaffney (Labour, Centre-left): Doctors have warned that the political situation in Kashmir is leading to a shortage of medicines and that hospitals are being left unable to provide treatment for patients. This is because Kashmir receives over 90% of its medical supplies from India. If this situation is not resolved, Kashmir faces the real risk of a major public health crisis. What steps will the Government take to sort it out?
Leaving the EU: Diplomacy — House of Commons, 2019-09-03
Topic: Health
Emily Thornberry (Labour, Centre-left): I welcome the new Foreign Secretary to his position, and indeed his seemingly entirely new team—it is certainly position churn—and pay tribute to his predecessor, who served for 12 months with a concern and diligence that had been so sorely lacking for the previous two years. I hope the new Foreign Secretary will follow the right example The Foreign Secretary will be aware of the concern of people across the country with health conditions such as schizophrenia and epilepsy for whom, as the Yellowhammer leaks reveal, it will not be possible to stockpile medicines. They will be left exposed and at grave risk because of the shortages that will follow a no-deal Brexit. Can I ask him a simple question? Have the Government asked for legal advice on how coroners would be expected to record the deaths of anyone who loses their life after 31 October as a result of the entirely preventable medicine shortages?
Leaving the EU: Diplomacy — House of Commons, 2019-09-03
Topic: Health
Emily Thornberry (Labour, Centre-left): I thank the Foreign Secretary for his answer, but the truth is this: the whole point of the Yellowhammer leaks is that some essential medicines—the ones about which I am asking—cannot be stockpiled, which is why there is genuine concern for these individuals As a lawyer, the Secretary of State knows his case law as well I do. He will know that if dependent individuals are denied their medicine and die as a result, their cases may meet all the tests in the watershed cases of Jamieson, Khan and Staffordshire and justify a coroner’s finding that they died as a result of neglect. I will submit a freedom of information request today to obtain the advice that the Government have been given to that effect Is it not a shameful disgrace that, in 21st-century Britain, we are having to talk about people who are denied their medicine, and about people having access to "adequate’" supplies of food—the Foreign Secretary’s own words—so that this shameless, shameful Government can play games of brinkmanship with Brussels and generate the pretext for a general election? This is no way in which to run a country.
Defence and Security Equipment International Exhibition — House of Commons, 2019-09-03
Topic: Defense
Questions: Which (a) Ministers and (b) officials in his Department plan to attend the Defence and Security Equipment International exhibition in London in September 2019.
Ann Clwyd (Labour, Centre-left): I wish that that were true, but it is not I note that Saudi Arabia has been invited to the arms fair once again. Will the Minister tell the House whether the Government are now reviewing all current arms licences to Saudi Arabia following the recent judgment by the Court of Appeal, which instructed them to determine the likelihood of the use of that equipment in serious violation of international humanitarian law, given past violations?
Engagements — House of Commons, 2019-10-30
Topic: Health
Questions: On behalf of those on the Conservative Benches, may I wish my right hon. Friend the best of good fortune in the 12 December general election? While we live in a period of some uncertainty, there are 426 people who have thalidomide and very much rely on the health grant to give them dignity, care and support. That grant comes to an end in a few years’ time. As chairman of the thalidomide APPG, and on behalf of those 426 recipients, I urge my right hon. Friend to end their uncertainty as soon as possible by signalling a renewal of that grant. That would give them the peace of mind that, I hope the whole House agrees, they most certainly deserve.
Jeremy Bernard Corbyn (Labour, Centre-left): We all welcome the fact that Orkambi will now be able to be provided in this country under the NHS, and we thank those who campaigned for it. The shame is that we are not told what the deal is with the company concerned. As for the fabled 40 hospitals, that figure dropped to 20 and then finally dropped to six We learned this week that Government officials have met US pharmaceutical companies five times as part of the Prime Minister’s planned trade deal. The US has called for "full market access" to our NHS, which would mean prices of some of our most important medicines increasing by up to sevenfold. While the Government are having secret meetings with US corporations, it is patients here who continue to suffer. Can the Prime Minister explain why the number of people waiting longer for urgent cancer treatment has tripled over the past nine years?
Engagements — House of Commons, 2019-10-30
Topic: Health
Questions: On behalf of those on the Conservative Benches, may I wish my right hon. Friend the best of good fortune in the 12 December general election? While we live in a period of some uncertainty, there are 426 people who have thalidomide and very much rely on the health grant to give them dignity, care and support. That grant comes to an end in a few years’ time. As chairman of the thalidomide APPG, and on behalf of those 426 recipients, I urge my right hon. Friend to end their uncertainty as soon as possible by signalling a renewal of that grant. That would give them the peace of mind that, I hope the whole House agrees, they most certainly deserve.
Jeremy Bernard Corbyn (Labour, Centre-left): If he could just be patient for 30 seconds The Prime Minister claims that the NHS is safe in his hands; why, then, has NHS privatisation doubled under this Government, with nearly £10 billion being spent on private companies in our NHS?
Engagements — House of Commons, 2019-10-30
Topic: Health
Questions: On behalf of those on the Conservative Benches, may I wish my right hon. Friend the best of good fortune in the 12 December general election? While we live in a period of some uncertainty, there are 426 people who have thalidomide and very much rely on the health grant to give them dignity, care and support. That grant comes to an end in a few years’ time. As chairman of the thalidomide APPG, and on behalf of those 426 recipients, I urge my right hon. Friend to end their uncertainty as soon as possible by signalling a renewal of that grant. That would give them the peace of mind that, I hope the whole House agrees, they most certainly deserve.
Jeremy Bernard Corbyn (Labour, Centre-left): What we do not want is private companies like Virgin Care suing our NHS for contracts that they did not get. Our NHS should be focused on making people better, not making the wealthy few richer. National health service A&E departments have just had their worst September on record. This morning, the Royal College of Emergency Medicine said that this winter the NHS needs more than 4,000 extra beds. Will the Prime Minister explain why, under his Government, the number of people in England waiting for an operation has now reached a record high of 4.4 million?
Engagements — House of Commons, 2019-10-30
Topic: Health
Questions: On behalf of those on the Conservative Benches, may I wish my right hon. Friend the best of good fortune in the 12 December general election? While we live in a period of some uncertainty, there are 426 people who have thalidomide and very much rely on the health grant to give them dignity, care and support. That grant comes to an end in a few years’ time. As chairman of the thalidomide APPG, and on behalf of those 426 recipients, I urge my right hon. Friend to end their uncertainty as soon as possible by signalling a renewal of that grant. That would give them the peace of mind that, I hope the whole House agrees, they most certainly deserve.
Jeremy Bernard Corbyn (Labour, Centre-left): I am surprised that the Prime Minister can keep a straight face saying that, while his Government have cut so much from the Welsh Government’s budget. And that from a Government who have cut 15,000 beds from the NHS and who have cut £7 billion from social care. I do not know how he has the brass neck to say what he has just said. The reality is that his words are hollow. That is clear to anyone who has tried to get a GP appointment, who sees how overworked our NHS staff are when they visit a hospital and who sees the stress that NHS staff go through when they cannot deal with all the patients who are coming in. He needs to think about this Let me give an example. A lady called Gillian wrote to me this week. [Hon. Members: "Ah!"] Yes, it is a real case of a real person, and I will quote her letter if I may, Mr Speaker. Gillian says: "My mother died in February as a direct result of the GP shortage in the UK. Her last years were marred by long waits for treatments and for interventions…Whenever she got care, it was given by overstretched but dedicated people, but it always came after painful and debilitating delays." Why should that happen to Gillian’s mum or anybody else’s mum? The problem is the shortage of GPs, the shortage of nurses and the excessive waiting time for people with very difficult conditions and deep pain. They should be sympathised with and supported.
Grenfell Tower Inquiry — House of Commons, 2019-10-30
Topic: Defense
James Fitzpatrick (Labour, Centre-left): I, too, welcome the tone of the Prime Minister’s presentation and the Government’s position. My hon. Friend the Member for Dulwich and West Norwood (Helen Hayes) has just alluded to this, but does my right hon. Friend agree that there is a much bigger picture than phase 1? Phase 1 focuses on the fire brigade response mostly, and many in the media have targeted the fire brigade for criticism, some of which is not unfair, but they are targeting only the fire brigade, as opposed to waiting for the big picture. The inquiry was always going to take a long time, it is incomplete and there are others, including ourselves here in this Parliament, who have some responsibility for the conditions that led to the Grenfell tragedy taking place.